Motixafortide - APHEXDA subcutaneous injection | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

A prediction about severe impairment is not observed evidence

The mirror predicts little severe-renal effect but explicitly states that it was not evaluated.

Before applying: Keep this classified as PK-only; do not translate an expectation into a proven no-adjustment or dialysis regimen.

Evidence for this qualification

Source-specific qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - APHEXDA

Product / population: APHEXDA subcutaneous injection with filgrastim for hematopoietic stem-cell mobilization in the labeled multiple-myeloma setting.
Renal measure: Qualitative mild/moderate impairment; numerical renal bands not specified

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Renal dosing, restrictions and evidence limits

Population pharmacokinetics were not significantly affected by mildly or moderately reduced renal function. Severe-renal effects on clearance were not evaluated; the source predicts that a major effect is unlikely.

That prediction is not observed severe-renal evidence. The selected paragraph gives no numerical renal boundaries or complete renal dosing schedule. Keep the finding classified as PK-only and confirm the complete product protocol rather than interpreting missing adjustment instructions as proven unrestricted use.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/aphexda-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - APHEXDA

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

APHEXDA subcutaneous injection with filgrastim for hematopoietic stem-cell mobilization in the labeled multiple-myeloma setting.

Renal method: Qualitative mild/moderate impairment; numerical renal bands not specified
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A prediction about severe impairment is not observed evidence

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

pk prediction not validation

A prediction about severe impairment is not observed evidence

The mirror predicts little severe-renal effect but explicitly states that it was not evaluated.

How to use this: Keep this classified as PK-only; do not translate an expectation into a proven no-adjustment or dialysis regimen.

GlobalRPh RX List - APHEXDA

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Rxlist source

GlobalRPh RX List - APHEXDA

APHEXDA subcutaneous injection with filgrastim for hematopoietic stem-cell mobilization in the labeled multiple-myeloma setting.

Method: Qualitative mild/moderate impairment; numerical renal bands not specified

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope GlobalRPh RX List - APHEXDA

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/aphexda-drug/

Exact product and population

APHEXDA subcutaneous injection with filgrastim for hematopoietic stem-cell mobilization in the labeled multiple-myeloma setting.

RDM55-SCOPE-motixafortide-aphexda · Source section: Selected source product scopeRenal section finder

Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist Compare this source

GlobalRPh RX List - APHEXDA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · APHEXDA subcutaneous injection with filgrastim for hematopoietic stem-cell mobilization in the labeled multiple-myeloma setting.

Renal method: Qualitative mild/moderate impairment; numerical renal bands not specified
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM55-rxlist-motixafortide-aphexda-abd83e905f-C1 · Source locator: Clinical Pharmacology: Specific Populations - Renal Impairment

Source-specific limits

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Source identity and provenance

Source family: product_label_mirror
Source: https://globalrph.com/rx-list/aphexda-drug/
Retrieved: 2026-09-09
Renal-function method: Qualitative mild/moderate impairment; numerical renal bands not specified
Source date/version: Source revision date not established in selected retrieval.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 257868152fd22a616e01a2ce8622868df8fc51d94c8dbe62317d83582489abd2

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/rx-list/aphexda-drug/
Source retrieval: 2026-09-09. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: f1369421a3bef870d4134cb255c8408eb9c8df1d6a4cbb03d622b9c8bb13c089
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report